Overview Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects Status: Not yet recruiting Trial end date: 2024-09-01 Target enrollment: Participant gender: Summary To assess the efficacy of HRS9531 injection compared with placebo in weight reduction in overweight or obese subjects after 36 weeks of treatment. Phase: Phase 2 Details Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.